
@DURECTCorp @EASLnews Why no PR after the oral breaking session?
English
49 posts






$AVXL Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022 globenewswire.com/news-release/2…












